Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00459186
Status:
COMPLETED
Last Update Posted:
2016-05-16
First Post:
2006-01-23
Brief Title:
The Use of RAD001 With Docetaxel in the Treatment of Metastatic Androgen Independent Prostate Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
05-184
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Mary-Ellen Taplin MD
Responsible Party Title:
Associate Professor of Medicine HMS
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Oregon Health and Science University | OTHER |
| Novartis | INDUSTRY |
| Massachusetts General Hospital | OTHER |
| Beth Israel Deaconess Medical Center | OTHER |